Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

11 results
Display

Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment

Ahn SM, Choi J, Ye BD, Yang SK, Oh JS, Kim Y, Lee C, Yoo B, Park SH, Hong S

Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study

Shin SY, Park SJ, Kim Y, Im JP, Kim HJ, Lee KM, Kim JW, Jung SA, Lee J, Kang SB, Shin SJ, Kim ES, Kim YS, Kim TO, Kim HS, Park DI, Kim HK, Kim ES, Kim YH, Kim DH, Teng D, Kim JH, Kim W, Choi CH, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases

Background/Aims: This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC). Methods: A prospective, observational, multicenter study was conducted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study

Shin JY, Park HM, Lee MY, Jeon JY, Yoo HJ, Ye BD

Background/Aims: Although anti-tumor necrosis factor (TNF) agents have been widely used to treat ulcerative colitis (UC), the real-world incidence of suboptimal response to anti-TNF agents has not been thoroughly investigated,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study

Song JH, Kang EA, Park SK, Hong SN, Kim YS, Bang KB, Kim KO, Lee HS, Kang SB, Shin SY, Song EM, Im JP, Choi CH, Group of the Korean Association for the Study of Intestinal Diseases

Background/Aims: Our study aimed to evaluate the long-term outcomes and risk factors for relapse after anti-tumor necrosis factor (TNF)-α cessation in inflammatory bowel disease (IBD) patients because they are not well...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy

Phan H, Weideman RA, Cipher DJ, Feagins LA

Background/Aims: Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy

Kim J, Im JP, Yim JJ, Lee CK, Park DI, Eun CS, Jung SA, Shin JE, Lee KM, Cheon JH

BACKGROUND/AIMS: Anti-tumor necrosis factor (TNF) therapy is used widely for the treatment of inflammatory bowel disease (IBD). In the present study, the characteristics and outcomes of tuberculosis (TB) in IBD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis

Kang YM, Park YE, Park W, Choe JY, Cho CS, Shim SC, Bae SC, Suh CH, Cha HS, Koh EM, Song YW, Yoo B, Lee SS, Park MC, Lee SH, Arendt C, Koetse W, Lee SK

BACKGROUND/AIMS: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity. METHODS:...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy

Sung YK, Cho SK, Kim D, Won S, Choi CB, Kim TH, Jun JB, Yoo DH, Bae SC

BACKGROUND/AIMS: To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence of Tuberculosis in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents following Latent Tuberculosis Infection Screening Strategies

Sung YK, Cho SK, Won S, Choi CB, Kim TH, Jun JB, Yoo DH, Bae SC

OBJECTIVE: To compare the incidence of tuberculosis (TB) in rheumatoid arthritis (RA) patients using tumor necrosis factor (TNF) inhibitors following two strategies for latent tuberculosis infection (LTBI) screening: Tuberculin skin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pulmonary Cryptococcosis in a Patient with Ankylosing Spondylitis treated with Etanercept

Lim CH, Lee SH, Kim HY, Kim WS, Kang S, Kwon SW, Kim J, Park SY, An SH, Yu HM, Kim HR

Ankylosing spondylitis (AS) is a chronic inflammatory disorder, commonly characterized by inflammation of axial skeleton and development of enthesopathies. Tumor necrosis factor inhibitors (TNFi) shows good therapeutic responses in AS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Review of Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis

Song JS

Advanced knowledges of cellular and molecular biology led to the development of therapies of rheumatoid arthritis (RA). The introduction of biologic agents into clinical practice has had a profound effect...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr